Effectiveness of olanzapine in the treatment of anorexia nervosa: A systematic review and meta‐analysis

Abstract Objective Anorexia nervosa (AN) is a severe psychiatric disorder characterized by starvation and malnutrition, a high incidence of coexisting psychiatric conditions, and treatment resistance. The effect of pharmacotherapy has been controversial. Method A systematic review was conducted for...

Full description

Bibliographic Details
Main Authors: Ruijun Han, Qingtao Bian, Hao Chen
Format: Article
Language:English
Published: Wiley 2022-02-01
Series:Brain and Behavior
Subjects:
Online Access:https://doi.org/10.1002/brb3.2498
_version_ 1797754665485467648
author Ruijun Han
Qingtao Bian
Hao Chen
author_facet Ruijun Han
Qingtao Bian
Hao Chen
author_sort Ruijun Han
collection DOAJ
description Abstract Objective Anorexia nervosa (AN) is a severe psychiatric disorder characterized by starvation and malnutrition, a high incidence of coexisting psychiatric conditions, and treatment resistance. The effect of pharmacotherapy has been controversial. Method A systematic review was conducted for evidence of an effect of olanzapine versus placebo in adults or its effect as adjuvant treatment of AN in adolescents. Results A total of seven articles (304 patients with AN) were identified. There were four double‐blind, randomized studies examining the effect of olanzapine in the treatment of AN. The mean difference in body mass index (BMI) at the end of treatment between olanzapine and placebo was 0.67 kg/m2 (95% confidence interval (CI) 0.15–1.18 kg/m2; p = 0.01; I2 = 0%, p for heterogeneity < 0.79). The olanzapine groups showed a significant increase in BMI of 0.68 kg/m2 (95% CI 0.22–1.13 kg/m2; p < 0.001; I2 = 0%, p for heterogeneity = 0.74) compared to the placebo groups. Only two studies examined the effect of olanzapine as adjuvant treatment in adolescents and showed an increase in BMI of 0.66 kg/m2 (95% CI −0.36 to 1.67 kg/m2; p = 0.21; I2 = 11%, p for heterogeneity = 0.32). Discussion Olanzapine showed efficacy in the treatment of AN with an increased BMI at the end of treatment in adults. The effect of olanzapine as adjuvant treatment in adolescents remains unclear.
first_indexed 2024-03-12T17:36:53Z
format Article
id doaj.art-9203191604ab427f9694ace313ac9dbe
institution Directory Open Access Journal
issn 2162-3279
language English
last_indexed 2024-03-12T17:36:53Z
publishDate 2022-02-01
publisher Wiley
record_format Article
series Brain and Behavior
spelling doaj.art-9203191604ab427f9694ace313ac9dbe2023-08-04T10:55:38ZengWileyBrain and Behavior2162-32792022-02-01122n/an/a10.1002/brb3.2498Effectiveness of olanzapine in the treatment of anorexia nervosa: A systematic review and meta‐analysisRuijun Han0Qingtao Bian1Hao Chen2Department of Psychiatry Beijing Huilongguan Hospital Beijing ChinaDepartment of Psychiatry Beijing Huilongguan Hospital Beijing ChinaDepartment of Internal Medicine Teikyo University Hospital Tokyo JapanAbstract Objective Anorexia nervosa (AN) is a severe psychiatric disorder characterized by starvation and malnutrition, a high incidence of coexisting psychiatric conditions, and treatment resistance. The effect of pharmacotherapy has been controversial. Method A systematic review was conducted for evidence of an effect of olanzapine versus placebo in adults or its effect as adjuvant treatment of AN in adolescents. Results A total of seven articles (304 patients with AN) were identified. There were four double‐blind, randomized studies examining the effect of olanzapine in the treatment of AN. The mean difference in body mass index (BMI) at the end of treatment between olanzapine and placebo was 0.67 kg/m2 (95% confidence interval (CI) 0.15–1.18 kg/m2; p = 0.01; I2 = 0%, p for heterogeneity < 0.79). The olanzapine groups showed a significant increase in BMI of 0.68 kg/m2 (95% CI 0.22–1.13 kg/m2; p < 0.001; I2 = 0%, p for heterogeneity = 0.74) compared to the placebo groups. Only two studies examined the effect of olanzapine as adjuvant treatment in adolescents and showed an increase in BMI of 0.66 kg/m2 (95% CI −0.36 to 1.67 kg/m2; p = 0.21; I2 = 11%, p for heterogeneity = 0.32). Discussion Olanzapine showed efficacy in the treatment of AN with an increased BMI at the end of treatment in adults. The effect of olanzapine as adjuvant treatment in adolescents remains unclear.https://doi.org/10.1002/brb3.2498adjuvant treatmentanorexia nervosabody mass indexolanzapinepharmacotherapy
spellingShingle Ruijun Han
Qingtao Bian
Hao Chen
Effectiveness of olanzapine in the treatment of anorexia nervosa: A systematic review and meta‐analysis
Brain and Behavior
adjuvant treatment
anorexia nervosa
body mass index
olanzapine
pharmacotherapy
title Effectiveness of olanzapine in the treatment of anorexia nervosa: A systematic review and meta‐analysis
title_full Effectiveness of olanzapine in the treatment of anorexia nervosa: A systematic review and meta‐analysis
title_fullStr Effectiveness of olanzapine in the treatment of anorexia nervosa: A systematic review and meta‐analysis
title_full_unstemmed Effectiveness of olanzapine in the treatment of anorexia nervosa: A systematic review and meta‐analysis
title_short Effectiveness of olanzapine in the treatment of anorexia nervosa: A systematic review and meta‐analysis
title_sort effectiveness of olanzapine in the treatment of anorexia nervosa a systematic review and meta analysis
topic adjuvant treatment
anorexia nervosa
body mass index
olanzapine
pharmacotherapy
url https://doi.org/10.1002/brb3.2498
work_keys_str_mv AT ruijunhan effectivenessofolanzapineinthetreatmentofanorexianervosaasystematicreviewandmetaanalysis
AT qingtaobian effectivenessofolanzapineinthetreatmentofanorexianervosaasystematicreviewandmetaanalysis
AT haochen effectivenessofolanzapineinthetreatmentofanorexianervosaasystematicreviewandmetaanalysis